Xlife Sciences AG (XSWX:XLS) Total Stockholders Equity: CHF286.53 Mil (As of Dec. 2025)


XSWX:XLS Xlife Sciences AG XSWX:XLS
52 GF Score
Price CHF18.60
GF Value CHF7.24
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Total Stockholders Equity?

Xlife Sciences AG XSWX:XLS +2.48% 52 Total Stockholders Equity is CHF286.53 Mil as of Dec. 2025. GuruFocus rates XSWX:XLS with a GF Score™ of 52/100 and a GF Value™ of CHF7.24 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF286.53 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Xlife Sciences AG's Book Value per Share for the quarter that ended in Dec. 2025 was CHF49.68. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Xlife Sciences AG's Debt-to-Equity for the quarter that ended in Dec. 2025 was 0.21.

Xlife Sciences AG  (XSWX:XLS) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Xlife Sciences AG's Book Value per Share for the quarter that ended in Dec. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(286.529-0)/5.768
=49.68

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Xlife Sciences AG's Debt-to-Equity for the quarter that ended in Dec. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(6.636 + 53.366) / 286.529
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Total Stockholders Equity Related Terms

Xlife Sciences AG Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Total Stockholders Equity Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 211.23 235.23 268.17 305.26 286.53

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 268.17 272.83 305.26 303.42 286.53
XSWX:XLS
52GF Score
Xlife Sciences AG XSWX:XLS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of CHF286.53 Mil mean?
Xlife Sciences AG (XSWX:XLS) has a Total Stockholders Equity of CHF286.53 Mil as of Dec. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Total Stockholders Equity too high?
Xlife Sciences AG's current Total Stockholders Equity is CHF286.53 Mil. Overall, Xlife Sciences AG has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Total Stockholders Equity compare to VRTX and REGN?
Xlife Sciences AG's Total Stockholders Equity of CHF286.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Xlife Sciences AG and its competitors. Xlife Sciences AG's current Total Stockholders Equity is CHF286.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.24, compared to a current price of CHF18.60 — trading 156.9% above its estimated fair value. The current Total Stockholders Equity is CHF286.53 Mil. Xlife Sciences AG's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Total Stockholders Equity is CHF286.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of CHF18.60 is trading 156.9% above its estimated GF Value™ of CHF7.24. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for XSWX:XLS:

  • Total Stockholders Equity: CHF286.53 Mil
  • GF Value™: CHF7.24 vs. price of CHF18.60 (156.9% above fair value)
  • GF Score™: 52/100 with 10 warning signs

No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Germany
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score

Get the complete analysis for XSWX:XLS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF18.60
Price
CHF7.24
GF Value